# StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis

> **NCT03882177** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 16 (actual)

## Conditions studied

- Tuberculosis
- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Pravastatin
- **DRUG:** Rifafour
- **DIETARY_SUPPLEMENT:** Vitamin B6

## Key facts

- **NCT ID:** NCT03882177
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-21
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-12-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882177, "StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03882177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*